A groundbreaking clinical trial has demonstrated the potential of an AI-designed vaccine aimed at providing broad protection against all variants of the coronavirus SARS-CoV-2. Developed by DIOSynVax, a spinout from the University of Cambridge, this vaccine marks the first instance of an entirely AI-generated vaccine being tested in human subjects.
The vaccine, named pEVAC-PS, utilizes a DNA plasmid-based, needle-free delivery system. It was engineered using extensive genetic data collected from global surveillance programs that monitor Sarbeco coronaviruses, which include COVID-19. The AI platform designed a "super-antigen" that encompasses common features across this group of viruses. In a trial involving 39 volunteers, the vaccine not only proved safe but also elicited immune responses against SARS-CoV-2 and related viruses, including those found in bats, which pose future pandemic risks.
This innovative approach could pave the way for vaccines targeting other viral families, such as Ebola, which is currently causing outbreaks in regions like the Democratic Republic of the Congo and Uganda. Lead investigator Prof. Saul Faust emphasized the need for proactive vaccine development, stating that traditional "reactive" methods often lag behind the rapid evolution of viruses, leading to mismatched vaccines at the time of outbreaks.
The trial, conducted at facilities in Cambridge and Southampton, revealed that while the immune responses were modest and varied, they support the concept of using super-antigens for broader vaccine efficacy. Prof. Jonathan Heeney noted that this shift from reactive to proactive vaccine development could save millions of lives and help prevent future lockdowns. A larger phase 2 trial is planned to further evaluate the vaccine's effectiveness across diverse populations, with the aim of confirming its protective capabilities as viruses continue to mutate.